Skip to main content

Advertisement

Table 2 Distribution of patient demographics and clinical characteristics before treatment

From: Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial

Characteristics Patients
No. %
Age, years
 Median 43
 Range 19-59
Sex
 Male 43 72.9
 Female 16 27.1
Histology, WHO typea
 III 59 100.0
EBV DNA copy no. (pre-treatment)
 Low (≤4000 copies/ml) 32 54.2
 High (>4000 copies/ml) 22 37.3
 NA 5 8.5
T stageb
 2 4 6.8
 3 30 50.8
 4 25 42.4
N stageb
 0 3 5.1
 1 26 44.1
 2 23 39.0
 3 7 11.9
Clinical stageb,c
 III 29 49.2
 IVa 23 39.0
 IVb 7 11.9
ECOG score
 0 3 5.1
 1 56 94.9
  1. Abbreviation ECOG Eastern Cooperative Oncology Group; NA not available
  2. aIII, undifferentiated nonkeratinizing carcinoma
  3. bAccording to the 7th edition AJCC staging system
  4. cIII, T3N0-2 M0, T1-2N2M0; IVa, T4N0-2 M0; IVb, T1-4N3M0